Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Up 7.62%
As of Friday, November 06, Aclaris Therapeutics, Inc.’s ACRS share price has surged by 7.62%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Commentary & Analysis
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Down 6.33%
As of Tuesday, October 27, Aclaris Therapeutics, Inc.’s ACRS share price has dipped by 6.33%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Up 7.47%
As of Tuesday, October 20, Aclaris Therapeutics, Inc.’s ACRS share price has surged by 7.47%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Up 5.15%
As of Thursday, October 08, Aclaris Therapeutics, Inc.’s ACRS share price has surged by 5.15%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Down 8.51%
As of Wednesday, October 07, Aclaris Therapeutics, Inc.’s ACRS share price has dipped by 8.51%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $559.5 | $409.9 | 40% |
|
| Shares Out (Mil) | 142.7 | 44.5 | 69% |
|
| Institutional Ownership | 96.1% | 81.1% | 69% |
|
| Float (Mil) | 109.0 | 45.7 | 62% |
|
| Beta | na | 0.72 | na |
|
| Avg Daily Volume (000s) | 2,695 | 284 | 84% |
|
| Price Change (52-week) |
53.0% | 52.7% | 87% |
|
| Growth | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 3.7% | 5.7% | 31% |
|
| Net Income (5yr) | (4.9%) | (2.0%) | 34% |
|
| EPS (5yr) | 15.1% | 14.9% | 57 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 34.4% | (15.1%) | 88% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 11 | 11 | |
| Current EPS | ($0.162) | ($0.641) | ($0.722) | |
| Month Ago EPS | ($0.165) | ($0.644) | ($0.787) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.173) | ($0.667) | ($0.802) | |
| Year/Year Chg | 7.3% | 20.9% | 44.5% | |
| Financials | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8 | $326 | 8% |
|
| Net Income (TTM) (Mil) | ($76) | ($11) | 13% |
|
| EPS (TTM) | ($0.586) | ($0.600) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($62) | ($6) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($6) | $2 | 34% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 18% |
|
| Enterprise Value (Q1) (Mil) | $641 | $466 | 36% |
|
| Valuation | ACRS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.06 | 1.96 | 77% |
|
| P/E | na | 20.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (816.7%) | 67.7% | 0% |
|
| Net Margin | na | 3.4% | na |
|
| ROA | (41.1%) | (21.5%) | 13% |
|
| ROE | (59.1%) | (21.0%) | 14% |
|
| Liabilities to Assets | 30.7% | 31.8% | 22% |
|
| F-Score | 3 | 3 | 18% |
|
Aclaris Therapeutics, Inc. did not pass any screens on 11/5/2026.
